PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Drug strategy blocks a leading driver of cancer

UCSF researchers solve decades-old challenge

2013-11-21
(Press-News.org) Contact information: Jeffrey Norris
jeffrey.norris@ucsf.edu
415-502-6397
University of California - San Francisco
Drug strategy blocks a leading driver of cancer UCSF researchers solve decades-old challenge The protein in cells that most often drives the development of cancers has eluded scientists' efforts to block it for three decades — until now.

Using a new strategy, UC San Francisco researchers have succeeded in making small molecules that irreversibly target a mutant form of this protein, called ras, without binding to the normal form. This feature distinguishes the molecules from all other targeted drug treatments in cancer, according to the researchers.

When tested on human lung cancer cells grown in culture, the molecules efficiently killed the ras-driven cancer cells.

Ras is abnormal in about three out of ten cancers. It is the most commonly activated protein in lung tumors, the leading cancer killer in the United States, as well as in colon cancers, the third leading cause of cancer death. Ras also is mutated in a vast majority of pancreatic cancers, which are almost always fatal, and the fourth leading cause of cancer death.

The protein has long been viewed as an obvious target for drug treatment in cancer, but since the 1980s drug candidates developed by several companies to block ras function have failed in clinical trials.

The UCSF research group, led by Kevan Shokat, PhD, a Howard Hughes Medical Institute investigator and chair of the UCSF Department of Cellular and Molecular Pharmacology, designed small molecules that attach irreversibly to ras within a previously unknown, normally short-lived pocket that appears on the mutant protein as it changes shape. Their work was published online November 20, 2013 in the journal Nature.

Many experienced pharmaceutical chemists had come to regard ras as undruggable, Shokat said. Among the failed strategies were conventional approaches aimed at designing small molecules to compete with the molecule called GTP, which naturally activates ras within the cell. GTP binds so tightly to ras that it is difficult for any drug to compete by binding instead and blocking activation.

But given its importance and the fact that few new cancer targets have been identified recently, drug companies have begun giving ras research another chance.

In its normal form, ras plays a key role in driving cell growth. When it is mutated, and thus activated in an uncontrolled manner, it triggers a chain of events within a tumor cell that includes abnormal activation or inhibition of other genes that then promote cancer. Some of the proteins encoded by these downstream genes have been targeted by promising treatments now in clinical trials. But tumors with abnormal ras often do not respond well to these single therapies, pushing researchers to evaluate various combinations of drugs.

The latest achievement further justifies a renewed interest in ras in the cancer research community and pharmaceutical industry, according to Frank McCormick, PhD, FRS, an expert on cancer biochemistry, the founder of Onyx Pharmaceuticals, director of the Helen Diller Family Comprehensive Cancer Center at UCSF, and now a leader of a new, $10-million-per-year initiative launched this year by the National Cancer Institutes to target ras.

"Cancers driven by ras are the most difficult to treat and are excluded from other targeted therapies, as they fail to respond," McCormick said. "Dr. Shokat and his team have taken a brilliantly innovative approach to this tough target, and, for the first time, have developed a strategy for targeting a mutant form of ras with exquisite specificity."

Two percent of all cancers have the specific mutation targeted in the study, including 7 percent of all lung cancers, according to Shokat. "We are confident that our findings can serve as the starting point for drug-discovery efforts targeting this specific mutation, and eventually other mutations," he said.

Additional Background

A mutated ras gene is the quintessential human "oncogene," one in which small alterations in the gene's DNA change its genetic blueprint, and thus the shape and function of the protein it encodes, or the amount of protein produced. The change converts the protein from one that helps guide normal growth and development into one that drives abnormal growth.

In some cases, a mutation that switches out just one of the DNA building blocks sequenced together to make a gene can alter the function of the resultant protein and lead to cancer.

Scores of oncogenes now are known, but, according to Shokat, "Ras was actually the first human oncogene found to be activated by a single point mutation. People have tried to drug every part of ras and looked at every nook and cranny on it and screened a million compounds and never found anything that inhibits it well."

Shokat and colleagues engineered molecules that inhibit the activity of ras in which a single point mutation caused a change in one specific amino acid among the hundreds that link and fold to determine the protein's form and function. The drug-like molecules depend on binding to a cysteine amino acid that is abnormally present near the newly identified pocket in the mutant ras.

Shokat is using the best ras inhibitor to come out of the study as a template for further drug development. UCSF has applied for a patent covering this lead compound, and licensed the intellectual property to Araxes Pharma, a new company co-founded by Shokat to advance development of a drug to target ras. The start-up has formed a partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

Because the molecules Shokat's research group created block only a mutant, cancer-driving form of ras, and not the normal ras found in the cells of healthy tissue, a drug developed according to this approach should have great specificity in targeting cancer while sparing normal tissue, Shokat said.

### Co-authors of the study include MD/PhD student Jonathan Ostrem, PhD; postdoctoral fellows Ulf Peters, PhD, and Martin Sos, PhD; and James Wells, PhD, chair of the Department of Pharmaceutical Chemistry in the UCSF School of Pharmacy.

UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. It includes top-ranked graduate schools of dentistry, medicine, nursing and pharmacy, a graduate division with nationally renowned programs in basic biomedical, translational and population sciences, as well as a preeminent biomedical research enterprise and two top-ranked hospitals, UCSF Medical Center and UCSF Benioff Children's Hospital.

Follow UCSF
UCSF.edu | Facebook.com/ucsf | Twitter.com/ucsf | YouTube.com/ucsf END


ELSE PRESS RELEASES FROM THIS DATE:

Long-term unemployment may accelerate aging in men

2013-11-21
Long-term unemployment may accelerate aging in men Men who are unemployed for more than two years show signs of faster ageing in their DNA, a new study has found. Researchers at Imperial College London and the University of Oulu, Finland studied DNA samples ...

Recessions experienced in mid-life linked to higher risk of cognitive decline later on

2013-11-21
Recessions experienced in mid-life linked to higher risk of cognitive decline later on Enforced job loss, part time working, and lower paid, lower status jobs may all take their toll Lay-offs and enforced part time work and lower paid, lower status jobs ...

Too much weekly sport seems to be as bad as too little for teen wellbeing

2013-11-21
Too much weekly sport seems to be as bad as too little for teen wellbeing But maximum benefit gained from double official recommendation on physical activity But the maximum benefit seems to be obtained from 14 hours of sport a week, which is double the ...

Excessive testosterone raises mortality risk in older men

2013-11-21
Excessive testosterone raises mortality risk in older men Study pinpoints optimal testosterone range for longer lifespan Chevy Chase, MD—Older men whose testosterone levels were neither low nor high tended to live longer, according to new research accepted ...

Metabolically healthy obesity does not guarantee clean bill of health

2013-11-21
Metabolically healthy obesity does not guarantee clean bill of health High BMI linked to increased risk of diabetes, cardiovascular disease Chevy Chase, MD—Obese people who are currently metabolically healthy face a higher risk of developing diabetes and ...

International Tree Nut Council funded study links nut consumption to reduced death rate

2013-11-21
International Tree Nut Council funded study links nut consumption to reduced death rate Largest study to date on nut consumption and mortality in New England Journal of Medicine In a study published today in the New England Journal of Medicine, researchers looked ...

Mount Sinai finds brain abnormalities linked to impaired self-awareness in cocaine addiction

2013-11-21
Mount Sinai finds brain abnormalities linked to impaired self-awareness in cocaine addiction Study challenges stigmatizing assumptions about cocaine addicted-individuals, points to targeted treatments based on quantifiable ...

PTSD raises risk for obesity in women

2013-11-21
PTSD raises risk for obesity in women Women with PTSD gain weight more rapidly than women without disorder Women with post-traumatic stress disorder (PTSD) gain weight more rapidly and are more likely to be overweight or obese than ...

The last croak for Darwin's frog

2013-11-21
The last croak for Darwin's frog Deadly amphibian disease chytridiomycosis has caused the extinction of Darwin's frogs, believe scientists from the Zoological Society of London (ZSL) and Universidad Andrés Bello (UNAB), Chile. Although habitat disturbance ...

Study is first to explain type of antimalarial drug resistance

2013-11-21
Study is first to explain type of antimalarial drug resistance WASHINGTON -- A Georgetown University professor published in the online journal PLOS ONE the first study explaining why drugs designed to fight off malaria stop working in some people with the disease. Malaria, ...

LAST 30 PRESS RELEASES:

New research boosts future whooping cough vaccines

Mechanistic understanding could enable better fast-charging batteries

No bones about it: new details about skeletal cell aging revealed

UNM scientists discover how nanoparticles of toxic metal used in MRI scans infiltrate human tissue

UMaine research examines best methods for growing Atlantic sea scallops

Medical cannabis could speed recovery, especially at community recovery homes

Study assesses U.S. image amid weakening of democracy

Two scientific researchers to receive 2025 Ralph L. Sacco Scholarships for Brain Health

Researchers improve chemical reaction that underpins products from foods to fuels

Texas Tech to develop semiconductor power devices through $6 million grant

Novel genomic screening tool enables precision reverse-engineering of genetic programming in cells

Hot Schrödinger cat states created

How cells repair their power plants

Oxygen is running low in inland waters—and humans are to blame

ACP’s Best Practice Advice addresses use of cannabis, cannabinoids for chronic noncancer pain

Beyond photorespiration: A systematic approach to unlocking enhanced plant productivity

How a small number of mutations can fuel outbreaks of western equine encephalitis virus

Exposure to wildfire smoke linked with worsening mental health conditions

Research uncovers hidden spread of one of the most common hospital-associated infections

Many older adults send their doctors portal messages, but who pays?

Fine particulate matter from 2020 California wildfires and mental health–related emergency department visits

Gender inequity in institutional leadership roles in US academic medical centers

Pancreatic cells ‘remember’ epigenetic precancerous marks without genetic sequence mutations

Rare combination of ovarian tumors found in one patient

AI-driven clinical recommendations may aid physician decision making to improve quality of care

Artificial intelligence has potential to aid physician decisions during virtual urgent care

ACP and Annals of Internal Medicine present breaking scientific news at ACP’s Internal Medicine Meeting 2025

New study reveals polymers with flawed fillers boost heat transfer in plastics

Signs identified that precede sudden arrhythmic death syndrome in young people

Discovery of bacteria's defence against viruses becomes a piece of the puzzle against resistance

[Press-News.org] Drug strategy blocks a leading driver of cancer
UCSF researchers solve decades-old challenge